Novartis, Novavax tout ability to quickly whip up pandemic flu vaccines

It's flu vaccine season, and as reports of H7N9 bird flu cases rise in China, Novartis ($NVS) and Novavax ($NVAX) both say they're now able to develop new immunizations within months of a viral strain's identification and sequencing. Report

Suggested Articles

China's role as a major producer of global API has come under scrutiny, but so far global tensions haven't affected supply, the FDA said.

Reblozyl, a key drug in Bristol Myers Squibb's Celgene merger, has won a key FDA nod to treat patients with myelodysplastic syndromes.

Wealthy individuals typically don't set out to waste billions of dollars, but amid the COVID-19 pandemic, that’s exactly what Bill Gates plans to do.